Why Compugen Shares Are Trading Higher By Over 200%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Portfolio Pulse from Avi Kapoor
Compugen Ltd. (CGEN) shares soared by over 200% after Gilead Sciences announced an exclusive licensing agreement for Compugen's pre-clinical immunotherapy program. Other stocks also moved significantly in Tuesday's mid-day session, with various companies experiencing gains due to positive developments such as FDA approvals, business accreditations, and favorable analyst upgrades. Conversely, some stocks fell sharply due to negative events like pricing of public offerings, discontinuation of joint development programs, and unfavorable patent litigation outcomes.

December 19, 2023 | 6:34 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Compugen Ltd. shares surged after Gilead Sciences agreed to license its immunotherapy program, indicating strong market confidence in the company's potential.
The sharp increase in CGEN's stock price is a direct result of the licensing agreement with Gilead, which is a significant validation of Compugen's immunotherapy program and suggests potential for future revenue growth.
CONFIDENCE 90
IMPORTANCE 95
RELEVANCE 100